Achieve Life Science

56 articles with Achieve Life Science

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards

  8/13/2021

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics.

• Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen

  8/11/2021

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,083,715 and U.S. Patent No. 11,083,716 covering the novel 3.0 mg three times daily cytisinicline dosing regimen.

• Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update

  8/11/2021

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced second quarter 2021 financial results and provided an update on the cytisinicline clinical development program.

• Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021

  5/4/2021

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that it will report its first quarter 2021 financial results and provide an update on the cytisinicline development program on Thursday, May 13, 2021 at 4:30PM EDT.

• Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option

  12/7/2020

  Achieve Life Sciences, Inc. announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of $7.00, for total gross proceeds of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

• Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update

  11/12/2020

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced third quarter 2020 financial results and provided an update on the cytisinicline clinical development program.

• Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020

  10/27/2020

  Achieve Life Sciences, Inc. announced the Company will host a Key Opinion Leader virtual roundtable event on cytisinicline and smoking cessation on Tuesday, November 17th, 2020, at 12:00PM EST.

• Achieve Life Sciences Announces to Present at the MicroCap Best Ideas Conference, October 13, 2020

  10/8/2020

  Achieve Life Sciences, Inc. announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually October 13th - 16th, 2020.

• Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

  10/7/2020

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced initiation of the Phase 3 ORCA-2 clinical trial.

• Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering

  8/4/2020

   Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 476,187 shares of its common stock at a price to the

• Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

  7/28/2020

  Achieve Life Sciences, Inc. announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020.

• Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program

  5/14/2020

  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2020 financial results and provided an update on the cytisinicline clinical

• Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020

  5/5/2020

  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its first quarter 2020 financial results on Thursday, May 14, 2020. Compa

• Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program

  11/6/2019

  Achieve Life Sciences, Inc. provided an update on the cytisinicline clinical development program and announced third quarter 2019 financial results.

• Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019

  10/31/2019

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019.

• Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study

  9/30/2019

  Achieve Life Sciences, Inc. announced completion of their maximum tolerated dose study.

• Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

  9/13/2019

  Achieve Life Sciences, Inc. announced that two presentations featuring final data from the Phase 2b ORCA-1 trial will be conducted at the SRNT-E Annual Conference on Friday, September 13th in Oslo.

• Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial

  9/5/2019

  Achieve Life Sciences, Inc. announced the Company will host its first investor day on Friday, September 20, 2019 in New York City.

• Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences

  9/4/2019

  Achieve Life Sciences, Inc. announced that John Bencich, Chief Financial and Operating Officer, will present at two upcoming investor conferences.